Interest of a new humanized anti-CD20 antibody in relapsed or refractory LLC

被引：0
|
作者：
Cluzeau, Thomas
机构：
来源：
HEMATOLOGIE | 2008年 / 14卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：104 / 105
页数：3
相关论文
共 50 条
  • [1] Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris
    Ellebrecht, Christoph T.
    Choi, Eun J.
    Allman, David M.
    Tsai, Donald E.
    Wegener, William A.
    Goldenberg, David M.
    Payne, Aimee S.
    [J]. JAMA DERMATOLOGY, 2014, 150 (12) : 1331 - 1335
  • [2] VELTUZUMAB Humanized Anti-CD20 Monoclonal Antibody Oncolytic
    Bhat, S. A.
    Czuczman, M. S.
    [J]. DRUGS OF THE FUTURE, 2011, 36 (07) : 519 - 526
  • [3] The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Christian, Beth A.
    Poi, Ming
    Jones, Jeffrey A.
    Porcu, Pierluigi
    Maddocks, Kami
    Flynn, Joseph M.
    Benson, Don M.
    Phelps, Mitch A.
    Wei, Lai
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 701 - 710
  • [4] Anti-lymphoma activity of a new humanized anti-CD20 monoclonal antibody, hA20
    Goldenberg, DM
    On, ZX
    Horak, ID
    Hansen, H
    Stein, R
    [J]. FASEB JOURNAL, 2003, 17 (07): : C123 - C123
  • [5] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Alinari, Lapo
    Earl, Christian Tyler
    Wilding, Emily
    Quinion, Carl
    Lustberg, Mark
    Benson, Don M., Jr.
    Jones, Jeffrey A.
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    [J]. BLOOD, 2010, 116 (21) : 1148 - 1149
  • [6] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
    Christian, Beth
    Alinari, Lapo
    Jones, Jeffrey A.
    Benson, Don M., Jr.
    Flynn, Joseph M.
    Porcu, Pierluigi
    Lustberg, Mark E.
    Phelps, Mitchell
    Poi, Ming
    Chung, Diana
    Quinion, Carl
    Byrd, John C.
    Wegener, William
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    [J]. BLOOD, 2011, 118 (21) : 1584 - 1584
  • [7] Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
    Tobinai, Kensei
    Ogura, Michinori
    Kobayashi, Yukio
    Uchida, Toshiki
    Watanabe, Takashi
    Oyama, Takashi
    Maruyama, Dai
    Suzuki, Tatsuya
    Mori, Masakazu
    Kasai, Masanobu
    Cronier, Damien
    Wooldridge, James E.
    Koshiji, Minori
    [J]. CANCER SCIENCE, 2011, 102 (02) : 432 - 438
  • [8] OBINUTUZUMAB Humanized Anti-CD20 Monoclonal Antibody Apoptosis Inducer Oncolytic
    Karlin, L.
    Salles, G.
    [J]. DRUGS OF THE FUTURE, 2011, 36 (09) : 657 - 662
  • [9] Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)
    Marzano, Angelo V.
    Fanoni, Daniele
    Venegoni, Luigia
    Berti, Emilio
    Caputo, Ruggero
    [J]. DERMATOLOGY, 2007, 214 (04) : 310 - 318
  • [10] Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva
    Nückel, H
    Meller, D
    Steuhl, KP
    Dührsen, U
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (04) : 258 - 262
12345